Key result
pLVAD support during unstable VT ablation is linked to ~137% higher VT termination rates.
Why the study?
Mechanical cardiac support is increasingly used during ablation of unstable VT, but little information is available regarding its potential hemodynamic benefits.
Does percutaneous left ventricular assist device (pLVAD) support improve procedural mapping time and VT termination in patients with structural heart disease and hemodynamically unstable VT?
Observational (n=22)
Does percutaneous left ventricular assist device (pLVAD) support improve procedural mapping time and VT termination in patients with structural heart disease and hemodynamically unstable VT?
pLVAD support during ablation of unstable VT safely maintains end-organ perfusion, allowing for extended periods of mapping and leading to higher rates of VT termination during the procedure.
Answers are grounded in this paper and cite their sources.
May facilitate extended mapping in unstable VT ablation; hypothesis-generating and requires prospective trials before practice change.
OBJECTIVES: Our goal was to investigate the effects of percutaneous left ventricular assist device (pLVAD) support during catheter ablation of unstable ventricular tachycardia (VT). BACKGROUND: Mechanical cardiac support during ablation of unstable VT is being increasingly used, but there is little available information on the potential hemodynamic benefits. METHODS: Twenty-three consecutive procedures in 22 patients (ischemic, n = 11) with structural heart disease and hemodynamically unstable VT were performed with either pLVAD support (n = 10) or no pLVAD support (intra-aortic balloon pump counterpulsation, n = 6; no support, n = 7). Procedural monitoring included vital signs, left atrial pressure, arterial blood pressure, cerebral perfusion/oximetry, VT characteristics, and ablation outcomes. RESULTS: The pLVAD group was maintained in VT significantly longer than the non-pLVAD group (66.7 min vs. 27.5 min; p = 0.03) and required fewer early terminations of sustained VT for hemodynamic instability (1.0 vs. 4.0; p = 0.001). More patients in the pLVAD group had at least 1 VT termination during ablation than non-pLVAD patients (9 of 10 [90%] vs. 5 of 13 [38%]; p = 0.03). There were no differences between groups in duration of cerebral deoxygenation, hypotension or perioperative changes in left atrial pressure, brain natriuretic peptide levels, lactic acid, or renal function. CONCLUSIONS: In patients with scar-related VT undergoing catheter ablation, pLVAD support was able to safely maintain end-organ perfusion despite extended periods of hemodynamically unstable VT. Randomized studies are necessary to determine whether this enhanced ability to perform entrainment and activation mapping will translate into a higher rate of clinical success.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2011) conducted an observational in structural heart disease and hemodynamically unstable ventricular tachycardia (n=22). percutaneous left ventricular assist device (pLVAD) support vs. no pLVAD support (intra-aortic balloon pump counterpulsation or no support) was evaluated on at least 1 VT termination during ablation (p=0.03). Percutaneous LVAD support during catheter ablation of unstable VT resulted in higher rates of VT termination during ablation compared to no pLVAD support.
Synapse has enriched 10 related papers. Consider them for comparative context: